Historical record - last NADAC publication: 10/18/2023
Product Information
KOMBIGLYZE XR 5-1,000 MG TAB is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $15.5404 per EA under NDC 00310614530. Its NADAC has been published 508 times since Jan 28, 2015.
Strength
1000; 5 mg/1; mg/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310614530
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Last Updated
10/18/2023
Active Ingredients
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA200678On Market Since
12/4/2014
Pharmacological Classes
Price Statistics
The NADAC for KOMBIGLYZE XR 5-1,000 MG TAB has been published 508 times since Jan 28, 2015, and over the history we have for it it has risen 47.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.5404 per EA |
|---|---|
| All-time high | $15.5404 (Oct 16, 2024) |
| All-time low | $10.5200 (Oct 21, 2015) |
| Median price | $13.4504 |
| Average price | $13.5739 |
| Largest weekly change | +11.8% (Dec 9, 2015) |
| Weeks tracked | 508 |
| Tracking since | Jan 28, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of KOMBIGLYZE XR 5-1,000 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for KOMBIGLYZE XR 5-1,000 MG TAB, manufactured by AstraZeneca Pharmaceuticals LP, is $15.5404 per EA (NDC 00310614530), effective Oct 16, 2024.
How has the price of KOMBIGLYZE XR 5-1,000 MG TAB changed over time?
Over the history we have for it, the NADAC for KOMBIGLYZE XR 5-1,000 MG TAB has risen 47.6%. It has been tracked across 508 weekly CMS publications since Jan 28, 2015.
What are the highest and lowest recorded NADAC prices for KOMBIGLYZE XR 5-1,000 MG TAB?
Since Jan 28, 2015, the NADAC for KOMBIGLYZE XR 5-1,000 MG TAB has ranged from a low of $10.5200 (Oct 21, 2015) to a high of $15.5404 (Oct 16, 2024), with a median of $13.4504 per EA.
Are there cheaper alternatives to KOMBIGLYZE XR 5-1,000 MG TAB?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of KOMBIGLYZE XR 5-1,000 MG TAB, so no direct lower-cost alternative is listed.
Who manufactures KOMBIGLYZE XR 5-1,000 MG TAB?
KOMBIGLYZE XR 5-1,000 MG TAB (NDC 00310614530) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.
Related Drugs
Same classification